Effect of mindfulness-based cognitive therapy in patients with inflammatory bowel disease

Not Applicable

Conditions: Condition 1: Mindfulness-based cognitive therapy(MBCT). Condition 2: Crohn's disease. Condition 3: Ulcerative colitis. Condition 4: Depression. Condition 5: Anxiety.
Crohn's disease [regional enteritis]
Ulcerative colitis
Major depressive disorder, single episode, mild
Anxiety disorder, unspecified
F32.0
F41.9

Registration Number: IRCT20200219046553N1

Lead Sponsor: Kashan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 50

Inclusion Criteria

Having informed consent to participate in research
- Age 18-60 years
- Confirmed diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) (by a physician)
- Patients should be in the active phase of IBD disease (Mild to moderate, moderate to severe) , not in the remission ,that accompanied by a decrease in symptoms
- In the Anxiety, Depression, Stress DASS-21 questionnaire, the individual's score on the depression scale of 10 or higher and / or on the anxiety scale of 8 or higher and / or on the stress scale of 15 or higher
- Ability to do light exercise (for example, to lift arms above the head or bend knees) because part of the practices in the program require this movement
- Able to commit to attend the eight sessions (participants should consider their personal circumstances to assess if this is practical and feasible for them)
- To be able to commit to do home practice of up to 45 minutes daily over the 8 weeks of the study (this is a core component of the program)
- No change of antidepressants (dose or type) within the last 3 months

Exclusion Criteria

- Major psychiatric illness.(The treatment for a major psychiatric illness may interfere with the program)
- Active alcohol or drug dependency
-Scheduled for major surgery in the next 3 months
- Participation in a pharmacological study or psychological intervention study within the last 6 months or intention to participate in a pharmacological study during the duration of this study
- Have recently (within the last 3 months) been prescribed antidepressants
- Exacerbation of symptoms and need for change in IBD medication (dose or type) during the study